Talphera (TLPH) 10-Q 10 May 23 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 05, 2023
Document Information [Line Items]
Entity Central Index Key	0001427925
Entity Registrant Name	ACELRX PHARMACEUTICALS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-35068
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-2193603
Entity Address, Address Line One	25821 Industrial Boulevard, Suite 400
Entity Address, City or Town	Hayward
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94545
City Area Code	650
Local Phone Number	216-3500
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ACRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		10,924,294

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unuadited) - USD ($) $ in Thousands		Mar. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents		$ 13,353	$ 15,275	[1]
Restricted cash		0	5,000
Short-term investments		0	495	[1]
Prepaid expenses and other current assets		525	1,865	[1]
Assets of discontinued operations		3,476	1,931
Total current assets		17,354	24,566	[1]
Operating lease right-of-use assets		49	96	[1]
In-process research and development asset		8,819	8,819
Other assets		70	70	[1]
Assets of discontinued operations		0	13,936	[1]
Total assets		26,292	47,487	[1]
Current Liabilities:
Accounts payable		1,398	1,256	[1]
Accrued and other liabilities		1,418	2,431	[1]
Long-term debt, current portion		3,318	5,363	[1]
Operating lease liabilities, current portion		51	100	[1]
Liabilities of discontinued operations		3,278	4,620
Total current liabilities		9,463	13,770	[1]
Warrant liability		1,787	7,098
Other long-term liabilities		800	810	[1]
Liabilities of discontinued operations		0	3,995
Total liabilities		12,050	25,673	[1]
Commitments and Contingencies
Common stock, $0.001 par value—200,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 10,924,294 and 8,243,680 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	[2]	11	8	[1]
Additional paid-in capital	[2]	448,212	447,635	[1]
Accumulated deficit	[2]	(433,981)	(425,829)	[1]
Total stockholders’ equity	[2]	14,242	21,814
Total Liabilities and Stockholders’ Equity		$ 26,292	$ 47,487
[1]The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.[2]Adjusted to give retroactive effect to a 1-for-20 reverse stock split effective as of 5:01 p.m. Eastern Time on October 25, 2022.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unuadited) (Parentheticals) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	10,924,294	8,243,680
Common stock, shares outstanding (in shares)	10,924,294	8,243,680

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating costs and expenses:
Research and development	$ 1,047	$ 836
Selling, general and administrative	4,281	4,100
Total operating costs and expenses	5,328	4,936
Loss from operations	(5,328)	(4,936)
Other income:
Interest expense	(119)	(390)
Interest income and other income, net	5,511	38
Non-cash interest income on liability related to sale of future royalties	0	673
Total other income	5,392	321
Net income (loss) from continuing operations	64	(4,615)
Net loss from discontinued operations– See Note 3	(8,216)	(4,059)
Net loss	$ (8,152)	$ (8,674)
Basic and diluted, continuing operations (in dollars per share)	$ 0	$ (0.63)
Basic and diluted, discontinued operations (in dollars per share)	(0.75)	(0.56)
Basic and diluted loss per share (in dollars per share)	$ (0.75)	$ (1.19)
Shares used in computing net loss per share of common stock, basic and diluted – See Note 10 (in shares)	10,893,954	7,281,187

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Preferred Stock [Member]	Total
Balance (in shares) at Dec. 31, 2021	6,840,967
Balance at Dec. 31, 2021	$ 7	$ 437,684	$ (473,584)	$ (35,893)
Stock-based compensation	$ 0	783	0	783
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes (in shares)	25,769
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes	$ 0	(58)	0	(58)
Issuance of common stock upon ESPP purchase (in shares)	7,671
Issuance of common stock upon ESPP purchase	$ 0	58	0	58
Net loss	$ 0	0	(8,674)	(8,674)
Issuance of common stock in connection with asset acquisition (in shares)	481,026
Issuance of common stock in connection with asset acquisition	$ 0	5,511	0	5,511
Balance (in shares) at Mar. 31, 2022	7,355,433
Balance at Mar. 31, 2022	$ 7	443,978	(482,258)	(38,273)
Balance (in shares) at Dec. 31, 2022	8,243,680
Balance at Dec. 31, 2022	$ 8	447,635	(425,829)	21,814	[1]
Stock-based compensation	$ 0	569	0	569
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes (in shares)	21,700
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes	$ 0	(22)	0	(22)
Exercise of prefunded warrants (in shares)	2,632,898
Exercise of prefunded warrants	$ 2	0	0	2
Issuance of common stock upon ESPP purchase (in shares)	26,016
Issuance of common stock upon ESPP purchase	$ 1	30	0	31
Net loss	$ 0	0	(8,152)	(8,152)
Balance (in shares) at Mar. 31, 2023	10,924,294
Balance at Mar. 31, 2023	$ 11	$ 448,212	$ (433,981)	$ 14,242	[1]
[1]Adjusted to give retroactive effect to a 1-for-20 reverse stock split effective as of 5:01 p.m. Eastern Time on October 25, 2022.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (8,152)	$ (8,674)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest income on liability related to royalty monetization	0	(673)
Depreciation and amortization	262	420
Non-cash interest expense related to debt financing	38	134
Stock-based compensation	569	783
Revaluation of warrant liability	(5,311)	0
Impairment of net assets held for sale	7,007	0
Impairment of fixed assets	1,065	0
Gain on termination of lease liabilities	(1,098)	0
Gain on extinguishment of debt liability	(400)	0
Other	(15)	2
Changes in operating assets and liabilities:
Accounts receivable	33	(24)
Inventories	61	57
Prepaid expenses and other assets	1,550	360
Accounts payable	100	249
Accrued liabilities	(960)	(1,512)
Operating lease liabilities	30	(56)
Deferred revenue	(29)	0
Net cash used in operating activities	(5,250)	(8,934)
Cash flows from investing activities:
Purchase of property and equipment	(100)	(89)
Purchase of investments	0	(6,175)
Cash paid for asset acquisition, net of cash acquired	0	(1,156)
Proceeds from maturities of investments	500	27,596
Net cash provided by investing activities	400	20,176
Cash flows from financing activities:
Payment of long-term debt	(2,083)	(2,083)
Net proceeds from issuance of common stock in connection with exercise of prefunded warrants	2	0
Net proceeds from issuance of common stock through equity plans	31	58
Payment of employee tax obligations related to vesting of restricted stock units	(22)	(58)
Net cash used in financing activities	(2,072)	(2,083)
Net change in cash, cash equivalents and restricted cash	(6,922)	9,159
Cash, cash equivalents and restricted cash—Beginning of period	20,275	12,663
Cash, cash equivalents and restricted cash—End of period	13,353	21,822
NONCASH INVESTING ACTIVITIES:
Purchases of property and equipment in accounts payable and accrued liabilities	0	1,275
Asset acquisition costs in accounts payable and accrued liabilities	0	531
Liability for hold back shares in connection with asset acquisition in other long-term liabilities	0	800
Issuance of common stock in connection with asset acquisition	$ 0	$ 5,511

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. The Company AcelRx Pharmaceuticals, Inc., or the Company, or AcelRx, was incorporated in Delaware on July 13, 2005 AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. On March 12, 2023, 30 April 3, 2023 ( 3, 11, On January 7, 2022, 4, not second 608, On July 14, 2021, 10 3 10 50 Liquidity and Going Concern The unaudited condensed consolidated financial statements for the three March 31, 2023 twelve 12 10 may SM third not may not not may third may may not Reverse Stock Split On September 23, 2022, 1 1 1 20, October 25, 2022, one not As the par value per share of the Company's common stock remained unchanged at $0.001 per share, the change in the common stock recorded at par value has been reclassified to additional paid-in-capital on a retroactive basis. All references to shares of common stock, stock options, restricted stock units and warrants and per share data for all periods presented in the accompanying unaudited condensed consolidated financial statements and notes thereto have been adjusted to reflect the Reverse Stock Split on a retroactive basis. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the United States. Securities and Exchange Commission, or SEC. Accordingly, they do not Operating results for the three March 31, 2023, not may December 31, 2023, December 31, 2022, December 31, 2022, 10 March 31, 2023. 10 December 31, 2022, Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not Recently Adopted Accounting Pronouncements In June 2016, 326, January 1, 2023. 326 not The Company does not not Significant Accounting Policies The Company’s significant accounting policies are detailed in its Annual Report on Form 10 December 31, 2022. no three March 31, 2023, 2022 10 In accordance with ASC 205 20 Presentation of Financial Statements: Discontinued Operations The Company’s DSUVIA business met the definition of a discontinued operation as of March 31, 2023. 3,

Note 2 - Investments and Fair V

Note 2 - Investments and Fair Value Measurement	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Investments and Fair Value Measurement Disclosure [Text Block]	2. Investments The Company classifies its marketable securities as available for sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (loss). As of March 31, 2023, December 31, 2022, one The tables below summarize the Company’s cash, cash equivalents and short-term investments (in thousands): As of March 31, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash, cash equivalents and restricted cash: Cash $ 1,716 $ — $ — $ 1,716 Money market funds 146 — — 146 U.S. government agency securities 5,677 — — 5,677 Commercial paper 5,814 — — 5,814 Total cash, cash equivalents, and restricted cash $ 13,353 $ — $ — $ 13,353 As of December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash, cash equivalents and restricted cash: Cash $ 13,275 $ — $ — $ 13,275 Money market funds 321 — — 321 U.S. government agency securities 2,444 — — 2,444 Commercial paper 4,235 — — 4,235 Total cash, cash equivalents and restricted cash 20,275 — — 20,275 Short-term investments: Commercial paper 495 — — 495 Total short-term investments 495 — — 495 Total cash, cash equivalents, restricted cash and short-term investments $ 20,770 $ — $ — $ 20,770 At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. Impairment is assessed at the individual security level. Factors considered in determining whether a loss resulted from a credit loss or other factors include the Company’s intent and ability to hold the investment until the recovery of its amortized cost basis, the extent to which the fair value is less than the amortized cost basis, the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any changes to the rating of the security by a rating agency, any adverse legal or regulatory events affecting the issuer or issuer’s industry, any significant deterioration in economic conditions. There were no material realized or unrealized gains or losses on marketable securities for the three March 31, 2023 twelve December 31, 2022. not three March 31, 2023. Fair Value Measurement The Company’s financial instruments consist of Level I and II assets. Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 third March 31, 2023 December 31, 2022, 2022 12, 2022 10 8, 820 The following tables set forth the fair value of the Company’s financial assets by level within the fair value hierarchy (in thousands): As of March 31, 2023 Fair Value Level I Level II Level III Assets Money market funds $ 146 $ 146 $ — $ — U.S. government agency securities 5,677 — 5,677 — Commercial paper 5,814 — 5,814 — Total assets measured at fair value $ 11,637 $ 146 $ 11,491 $ — Liabilities Warrant liability 1,787 — — 1,787 Total liabilities measured at fair value $ 1,787 $ — $ — $ 1,787 As of December 31, 2022 Fair Value Level I Level II Level III Assets Money market funds $ 321 $ 321 $ — $ — U.S. government agency securities 2,444 — 2,444 — Commercial paper 4,730 — 4,730 — Total assets measured at fair value $ 7,495 $ 321 $ 7,174 $ — Liabilities Warrant liability 7,098 — — 7,098 Total liabilities measured at fair value $ 7,098 $ — $ — $ 7,098 The following tables set forth a summary of the changes in the fair value of the Company’s Level III warrant liability for the three March 31, 2023 ( Three Months Ended March 31, 2023 Fair value—beginning of period $ 7,098 Change in fair value of 2022 Warrants liability (5,311 ) Fair value—end of period $ 1,787 There were no three March 31, 2023 December 31, 2022.

Note 3 - Discontinued Operation

Note 3 - Discontinued Operations	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	3. On March 12, 2023, The Company’s DSUVIA business met the definition of a discontinued operation as of March 31, 2023. March 31, 2023 December 31, 2022. March 31, 2023. April 3, 2023 ( 11, The following table presents the results of the discontinued operations for the three March 31, 2023 March 31, 2022 ( Three months ended March 31, ​ 2023 2022 Total revenues $ 501 $ 442 Cost of goods sold 711 414 Selling, general and administrative expense 683 3,608 Impairment of net assets held for sale 7,007 — Impairment of fixed assets 1,065 — Gain on termination of lease liabilities (1,098 ) — Research and development expenses 349 479 Loss from operations 8,216 4,059 Loss from discontinued operations before loss on disposal $ 8,216 $ 4,059 The following table summarizes the carrying amounts of major classes of assets and liabilities of discontinued operations for each of the periods presented (in thousands). ​ ​ March 31, 2023 December 31, 2022 Cash and cash equivalents $ — $ — Accounts receivable, net 276 309 Inventories 1,117 1,178 Prepaid expenses and other current assets 231 444 Property, plant and equipment, net 8,509 — Operating lease right-of-use assets 178 — Other assets 172 — Less: expected loss on sale of discontinued operations (7,007 ) — Total current assets of discontinued operations 3,476 1,931 Property, plant and equipment, net — 10,261 Operating lease right-of-use assets — 3,499 Other assets — 176 Total non-current assets of discontinued operations — 13,936 Total assets of discontinued operations $ 3,476 $ 15,867 ​ ​ ​ Accounts payable 618 784 Accrued liabilities 1,184 1,720 Operating lease liabilities, current portion 354 1,601 Note payable, current portion — 400 Deferred revenue, current portion 1,122 115 Total current liabilities of discontinued operations 3,278 4,620 Operating lease liabilities, net of current portion — 2,959 Deferred revenue, net of current portion — 1,036 Total non-current liabilities of discontinued operations — 3,995 Total liabilities of discontinued operations 3,278 8,615 Net assets of discontinued operations $ 198 $ 7,252 The following table presents the significant non-cash items and purchases of property, plant and equipment for the discontinued operations that are included in the accompanying unaudited condensed consolidated statements of cash flows (in thousands): ​ Three months ended ​ March 31, ​ 2023 2022 Cash flows from operating activities: Depreciation and amortization $ 215 $ 379 Stock-based compensation 19 145 Impairment of net assets held for sale 7,007 — Impairment of fixed assets 1,065 — Gain on termination of lease liabilities (1,098 ) — Gain on extinguishment of debt (400 ) — The following table represents the expected loss on sale of discontinued operations for the three March 31, 2023: March 31, 2023 Expected cash proceeds $ 2,723 Less: net assets transferred (8,840 ) Less: expected disposal costs (890 ) Expected loss on sale of discontinued operations, before income taxes (7,007 ) Income tax expense — Expected loss on sale of discontinued operations $ (7,007 ) Per ASC 450, three March 31, 2023.

Note 4 - In-license Agreement

Note 4 - In-license Agreement	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
In-license Agreement [Text Block]	4. On July 14, 2021, 10 3 10 50 The PFS Agreement has an initial term of ten 10 first December 31 first December 31 first January 1 April 30 five not six 6 Aguettant is entitled to receive up to $24.0 million in sales-based milestone payments. The Company will purchase each product from Aguettant at an agreed price, or the PFS Purchase Price, subject to adjustment. The Company will also make revenue share payments that, combined with the PFS Purchase Price, will range from 40% to 45% of net sales in the United States. The Company and Aguettant will agree on minimum sales obligations twelve 12 The Company has the right to grant sublicenses to its affiliates or, with the prior approval of Aguettant, third As of March 31, 2023, no See Note 11,

Note 5 - Long-term Debt

Note 5 - Long-term Debt	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Long-Term Debt [Text Block]	5. Loan Agreement with Oxford On May 30, 2019, May 30, 2019. As of March 31, 2023 December 31, 2022, three March 31, 2023, three March 31, 2022. See Note 11,

Note 6 - Leases

Note 6 - Leases	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	6. Office Lease On March 26, 2021, 25821 April 1, 2021. two three June 30, 2023, one three March 31, 2023 second 2023.

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Litigation On June 8, 2021, two 10 20 10b 5 December 16, 2021, March 7, 2022. three 10 20 10b 5 20A September 1, 2022, July 21, 2022. September 28, 2022, November 28, 2022, second three 10 20 January 30, 2023, second March 16, 2023, April 17, 2023, May 25, 2023. On July 6, 2021, ten September 30, 2021, October 26, 2021, November 17, 2021, three nine four December 6, 2021, four 1A. may The Company believes that these lawsuits are without merit and intends to vigorously defend against them. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may Termination Agreement and Mutual Release Between AcelRx and Catalent On March 12, 2023, August 15, 2019 September 24, 2020, March 31, 2021,

Note 8 - Warrants

Note 8 - Warrants	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Warrants Disclosure [Text Block]	8. The activity related to warrants during the three March 31, 2023, Common Warrants Weighted- Outstanding at December 31, 2022 7,824,933 $ 1.72 Pre-funded warrants exercised 2,632,898 $ 0.0001 Outstanding at March 31, 2023 5,192,035 $ 2.59 Exercisable at March 31, 2023 964,983 $ 4.89 The pre-funded warrants issued in December 2022 2022 three March 31, 2023. December 2022 2022 March 31, 2023, 2022 2, 11,

Note 9 - Stock-based Compensati

Note 9 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	9. The Company recorded total stock-based compensation expense for stock options, restricted stock units, or RSUs, and the Amended and Restated 2011 March 31, 2023 March 31, 2022 Research and development $ 93 $ 174 Selling, general and administrative 457 464 Discontinued operations 19 145 Total $ 569 $ 783 The following table summarizes restricted stock unit activity under the Company’s equity incentive plans: Weighted Number of Average Restricted Grant Date Stock Units Fair Value Restricted stock units outstanding, January 1, 2023 82,778 $ 16.97 Granted 44,091 1.76 Vested (34,606 ) 21.61 Forfeited (643 ) 17.91 Restricted stock units outstanding, March 31, 2023 91,620 $ 7.89 Upon vesting, certain of the Company’s RSUs may March 31, 2023, The following table summarizes stock option activity under the Company’s equity incentive plans: Number of Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) January 1, 2023 725,623 $ 52.98 Granted 264,520 1.76 Forfeited (1,950 ) 19.41 Expired (90,802 ) 83.75 Exercised — — March 31, 2023 897,391 $ 34.84 6.9 $ — Vested and exercisable options— March 31, 2023 459,397 $ 58.42 4.7 $ — Vested and expected to vest— March 31, 2023 897,391 $ 34.84 6.9 $ — The per-share weighted average grant date fair value of the options granted during the quarter ended March 31, 2023 Three months ended March 31, 2023 Expected term (in years) 6.3 Risk-free interest rate 3.9% Expected volatility 94% Expected dividend rate 0% As of March 31, 2023, March 31, 2023,

Note 10 - Net Loss Per Share of

Note 10 - Net Loss Per Share of Common Stock	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	10. The Company’s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, RSUs, and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive: Three Months Ended March 31, 2023 2022 RSUs, stock options and ESPP to purchase common stock 989,011 893,223 Common stock warrants 5,192,035 883,833 In addition, the shares held back and contingently issuable in connection with the Lowell Merger, as described in Note 4, 2022 10 not

Note 11 - Subsequent Events

Note 11 - Subsequent Events	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	11. Asset Purchase Agreement On April 3, 2023, March 12, 2023, 30 15 third third The Purchase Agreement contains customary representations, warranties, and covenants by each party. Alora agreed not six July 1, 2023, The Closing included the execution of the Amended DZUVEO Agreement (as defined below) and the Amended and Restated Supply Agreement (as defined below) between AcelRx and Aguettant, as well as certain ancillary agreements between AcelRx and Alora. Such ancillary agreements include (a) an intellectual property agreement, pursuant to which Alora granted fully-paid, royalty-free and perpetual licenses to AcelRx under certain specified intellectual property rights acquired by Alora under the Purchase Agreement for, among other things, the development, manufacture, commercialization and exploitation of certain products, including Zalviso, (b) a transition services agreement, pursuant to which, during the period specified therein, AcelRx will be paid to provide certain services (including, manufacturing technology transfer, supply chain, regulatory, and medical affairs services) to Alora, and distribute, on behalf of Alora, certain inventory of Product transferred to Alora under the Purchase Agreement, and (c) a marketing agreement, or the Marketing Agreement, pursuant to which AcelRx will have the exclusive right to market and offer Product for sale to DoD and Alora will pay to AcelRx 75% of net sales of Product sold to DoD, subject to adjustment in certain circumstances. Amendments to Certain Agreements Between AcelRx and Aguettant AcelRx and Aguettant are parties to (a) the License and Commercialization Agreement, dated July 14, 2021, December 6, 2021, Pursuant to the Amended DZUVEO Agreement, (a) Aguettant’s obligations to make sales-based milestone payments and to achieve certain levels of minimum sales terminated, (b) AcelRx agreed to manufacture and supply DZUVEO in the form of bulk products ( i.e. i.e. not Pursuant to the Purchase Agreement, AcelRx assigned the Amended DZUVEO Agreement and the Amended and Restated Supply Agreement to Alora. In addition, AcelRx and Aguettant are parties to the License and Commercialization Agreement, dated July 14, 2021, April 3, 2023, ( Repayment of Loan Agreement with Oxford In connection with the closing of the divestment of DSUVIA to Alora, the Company and Oxford agreed that the Company would repay the loan in full without any prepayment penalties or the payment of future remaining interest that otherwise would have been payable under the Loan. On April 3, 2023, no Amended and Restated 2022 On April 25, 2023, 2022

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Business Description of Entity [Policy Text Block]	The Company AcelRx Pharmaceuticals, Inc., or the Company, or AcelRx, was incorporated in Delaware on July 13, 2005 AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. On March 12, 2023, 30 April 3, 2023 ( 3, 11, On January 7, 2022, 4, not second 608, On July 14, 2021, 10 3 10 50 Liquidity and Going Concern The unaudited condensed consolidated financial statements for the three March 31, 2023 twelve 12 10 may SM third not may not not may third may may not
Reverse Stock Split, Policy [Policy Text Block]	Reverse Stock Split On September 23, 2022, 1 1 1 20, October 25, 2022, one not As the par value per share of the Company's common stock remained unchanged at $0.001 per share, the change in the common stock recorded at par value has been reclassified to additional paid-in-capital on a retroactive basis. All references to shares of common stock, stock options, restricted stock units and warrants and per share data for all periods presented in the accompanying unaudited condensed consolidated financial statements and notes thereto have been adjusted to reflect the Reverse Stock Split on a retroactive basis.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the United States. Securities and Exchange Commission, or SEC. Accordingly, they do not Operating results for the three March 31, 2023, not may December 31, 2023, December 31, 2022, December 31, 2022, 10 March 31, 2023. 10 December 31, 2022,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In June 2016, 326, January 1, 2023. 326 not The Company does not not Significant Accounting Policies The Company’s significant accounting policies are detailed in its Annual Report on Form 10 December 31, 2022. no three March 31, 2023, 2022 10 In accordance with ASC 205 20 Presentation of Financial Statements: Discontinued Operations The Company’s DSUVIA business met the definition of a discontinued operation as of March 31, 2023. 3,

Note 2 - Investments and Fair_2

Note 2 - Investments and Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	As of March 31, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash, cash equivalents and restricted cash: Cash $ 1,716 $ — $ — $ 1,716 Money market funds 146 — — 146 U.S. government agency securities 5,677 — — 5,677 Commercial paper 5,814 — — 5,814 Total cash, cash equivalents, and restricted cash $ 13,353 $ — $ — $ 13,353 As of December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash, cash equivalents and restricted cash: Cash $ 13,275 $ — $ — $ 13,275 Money market funds 321 — — 321 U.S. government agency securities 2,444 — — 2,444 Commercial paper 4,235 — — 4,235 Total cash, cash equivalents and restricted cash 20,275 — — 20,275 Short-term investments: Commercial paper 495 — — 495 Total short-term investments 495 — — 495 Total cash, cash equivalents, restricted cash and short-term investments $ 20,770 $ — $ — $ 20,770
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	As of March 31, 2023 Fair Value Level I Level II Level III Assets Money market funds $ 146 $ 146 $ — $ — U.S. government agency securities 5,677 — 5,677 — Commercial paper 5,814 — 5,814 — Total assets measured at fair value $ 11,637 $ 146 $ 11,491 $ — Liabilities Warrant liability 1,787 — — 1,787 Total liabilities measured at fair value $ 1,787 $ — $ — $ 1,787 As of December 31, 2022 Fair Value Level I Level II Level III Assets Money market funds $ 321 $ 321 $ — $ — U.S. government agency securities 2,444 — 2,444 — Commercial paper 4,730 — 4,730 — Total assets measured at fair value $ 7,495 $ 321 $ 7,174 $ — Liabilities Warrant liability 7,098 — — 7,098 Total liabilities measured at fair value $ 7,098 $ — $ — $ 7,098
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three Months Ended March 31, 2023 Fair value—beginning of period $ 7,098 Change in fair value of 2022 Warrants liability (5,311 ) Fair value—end of period $ 1,787

Note 3 - Discontinued Operati_2

Note 3 - Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	Three months ended March 31, ​ 2023 2022 Total revenues $ 501 $ 442 Cost of goods sold 711 414 Selling, general and administrative expense 683 3,608 Impairment of net assets held for sale 7,007 — Impairment of fixed assets 1,065 — Gain on termination of lease liabilities (1,098 ) — Research and development expenses 349 479 Loss from operations 8,216 4,059 Loss from discontinued operations before loss on disposal $ 8,216 $ 4,059 ​ March 31, 2023 December 31, 2022 Cash and cash equivalents $ — $ — Accounts receivable, net 276 309 Inventories 1,117 1,178 Prepaid expenses and other current assets 231 444 Property, plant and equipment, net 8,509 — Operating lease right-of-use assets 178 — Other assets 172 — Less: expected loss on sale of discontinued operations (7,007 ) — Total current assets of discontinued operations 3,476 1,931 Property, plant and equipment, net — 10,261 Operating lease right-of-use assets — 3,499 Other assets — 176 Total non-current assets of discontinued operations — 13,936 Total assets of discontinued operations $ 3,476 $ 15,867 ​ ​ ​ Accounts payable 618 784 Accrued liabilities 1,184 1,720 Operating lease liabilities, current portion 354 1,601 Note payable, current portion — 400 Deferred revenue, current portion 1,122 115 Total current liabilities of discontinued operations 3,278 4,620 Operating lease liabilities, net of current portion — 2,959 Deferred revenue, net of current portion — 1,036 Total non-current liabilities of discontinued operations — 3,995 Total liabilities of discontinued operations 3,278 8,615 Net assets of discontinued operations $ 198 $ 7,252 ​ Three months ended ​ March 31, ​ 2023 2022 Cash flows from operating activities: Depreciation and amortization $ 215 $ 379 Stock-based compensation 19 145 Impairment of net assets held for sale 7,007 — Impairment of fixed assets 1,065 — Gain on termination of lease liabilities (1,098 ) — Gain on extinguishment of debt (400 ) — March 31, 2023 Expected cash proceeds $ 2,723 Less: net assets transferred (8,840 ) Less: expected disposal costs (890 ) Expected loss on sale of discontinued operations, before income taxes (7,007 ) Income tax expense — Expected loss on sale of discontinued operations $ (7,007 )

Note 8 - Warrants (Tables)

Note 8 - Warrants (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Common Warrants Weighted- Outstanding at December 31, 2022 7,824,933 $ 1.72 Pre-funded warrants exercised 2,632,898 $ 0.0001 Outstanding at March 31, 2023 5,192,035 $ 2.59 Exercisable at March 31, 2023 964,983 $ 4.89

Note 9 - Stock-based Compensa_2

Note 9 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	March 31, 2023 March 31, 2022 Research and development $ 93 $ 174 Selling, general and administrative 457 464 Discontinued operations 19 145 Total $ 569 $ 783
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Weighted Number of Average Restricted Grant Date Stock Units Fair Value Restricted stock units outstanding, January 1, 2023 82,778 $ 16.97 Granted 44,091 1.76 Vested (34,606 ) 21.61 Forfeited (643 ) 17.91 Restricted stock units outstanding, March 31, 2023 91,620 $ 7.89
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) January 1, 2023 725,623 $ 52.98 Granted 264,520 1.76 Forfeited (1,950 ) 19.41 Expired (90,802 ) 83.75 Exercised — — March 31, 2023 897,391 $ 34.84 6.9 $ — Vested and exercisable options— March 31, 2023 459,397 $ 58.42 4.7 $ — Vested and expected to vest— March 31, 2023 897,391 $ 34.84 6.9 $ —
Performance Shares [Member]
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three months ended March 31, 2023 Expected term (in years) 6.3 Risk-free interest rate 3.9% Expected volatility 94% Expected dividend rate 0%

Note 10 - Net Loss Per Share _2

Note 10 - Net Loss Per Share of Common Stock (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2023 2022 RSUs, stock options and ESPP to purchase common stock 989,011 893,223 Common stock warrants 5,192,035 883,833

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)	Oct. 25, 2022 $ / shares	Sep. 23, 2022	Mar. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001		$ 0.001	$ 0.001
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20
Reverse Stock Split [Member] | Minimum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		10
Reverse Stock Split [Member] | Maximum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		30

Note 2 - Investments and Fair_3

Note 2 - Investments and Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale	$ 0	$ 0

Note 2 - Investments and Fair_4

Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Total cash, cash equivalents, and restricted cash	$ 13,353	$ 20,275	$ 21,822	$ 12,663
Total cash, cash equivalents, restricted cash and short-term investments		20,770
Total cash, cash equivalents and short-term investments, fair value		20,770
Marketable Securities [Member]
Short-term investment, amortized Cost		495
Short-term investment, fair value		495
Commercial Paper [Member] | Marketable Securities [Member]
Short-term investment, amortized Cost		495
Short-term investment, fair value		495
Cash and Cash Equivalents [Member] | Cash [Member]
Cash, amortized cost	1,716	13,275
Cash and cash equivalent, fair value	1,716	13,275
Cash and Cash Equivalents [Member] | Money Market Funds [Member]
Cash and cash equivalent, fair value	146	321
Money market funds, amortized cost	146	321
Cash and Cash Equivalents [Member] | US Government Agencies Debt Securities [Member]
Cash and cash equivalent, fair value	5,677
U.S. government agency securities	5,677
Cash and Cash Equivalents [Member] | U.S. Government Agency Securities [Member]
U.S. government agency securities		2,444
Cash and Cash Equivalents [Member] | Commercial Paper [Member]
Cash and cash equivalent, fair value		4,235
Short-term investment, amortized Cost	5,814
Short-term investment, fair value	$ 5,814
Commercial paper		$ 4,235

Note 2 - Investments and Fair_5

Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets, fair value	$ 11,637	$ 7,495
Liabilities, fair value	1,787	7,098
Warrant Liability [Member]
Liabilities, fair value	1,787
Fair Value, Inputs, Level 1 [Member]
Assets, fair value	146	321
Liabilities, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Warrant Liability [Member]
Liabilities, fair value	0
Fair Value, Inputs, Level 2 [Member]
Assets, fair value	11,491	7,174
Liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Warrant Liability [Member]
Liabilities, fair value	0
Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Liabilities, fair value	1,787	7,098
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]
Liabilities, fair value	1,787
Money Market Funds [Member]
Assets, fair value	146	321
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	146	321
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
US Government Agencies Debt Securities [Member]
Assets, fair value	5,677	2,444
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	5,677	2,444
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Commercial Paper [Member]
Assets, fair value	5,814	4,730
Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	5,814	4,730
Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	$ 0	$ 0

Note 2 - Investments and Fair_6

Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Fair value—beginning of period	$ 7,098
Change in fair value of 2022 Warrants liability	(5,311)
Fair value—end of period	$ 1,787

Note 3 - Discontinued Operati_3

Note 3 - Discontinued Operations (Details Textual) - DSUVIA [Member] - Discontinued Operations [Member] $ in Millions	Mar. 12, 2023 USD ($)
Disposal Group, Including Discontinued Operation, Consideration	$ 1.1
Disposal Group, Including Discontinued Operation, Percentage of Royalty on Commercial Sales	15%
Disposal Group, Including Discontinued Operation, Maximum Amount in Sales-based Milestone	$ 116.5
Department of Defense [Member]
Disposal Group, Including Discontinued Operation, Percentage of Royalty on Commercial Sales	75%

Note 3 - Discontinued Operati_4

Note 3 - Discontinued Operations - Summary of Discontinued Operation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Impairment of net assets held for sale	$ 7,007	$ 0
Impairment of fixed assets	1,065	0
Gain on termination of lease liabilities	(1,098)	0
Total current assets of discontinued operations	3,476		$ 1,931
Total non-current assets of discontinued operations	0		13,936	[1]
Total current liabilities of discontinued operations	3,278		4,620
Total non-current liabilities of discontinued operations	0		3,995
Gain on extinguishment of debt	(400)	0
DSUVIA [Member] | Discontinued Operations [Member]
Total revenues	501	442
Cost of goods sold	711	414
Selling, general and administrative expense	683	3,608
Impairment of net assets held for sale	7,007	0
Impairment of fixed assets	1,065	0
Gain on termination of lease liabilities	(1,098)	0
Research and development expenses	349	479
Loss from operations	8,216	4,059
Loss from discontinued operations before loss on disposal	8,216	4,059
Cash and cash equivalents	0		0
Accounts receivable, net	276		309
Inventories	1,117		1,178
Prepaid expenses and other current assets	231		444
Property, plant and equipment, net	8,509		0
Operating lease right-of-use assets	178		0
Other assets	172		0
Less: expected loss on sale of discontinued operations	(7,007)		0
Total current assets of discontinued operations	3,476		1,931
Property, plant and equipment, net	0		10,261
Operating lease right-of-use assets	0		3,499
Other assets	0		176
Total non-current assets of discontinued operations	0		13,936
Total assets of discontinued operations	3,476		15,867
Accounts payable	618		784
Accrued liabilities	1,184		1,720
Operating lease liabilities, current portion	354		1,601
Note payable, current portion	0		400
Deferred revenue, current portion	1,122		115
Total current liabilities of discontinued operations	3,278		4,620
Operating lease liabilities, net of current portion	0		2,959
Deferred revenue, net of current portion	0		1,036
Total non-current liabilities of discontinued operations	0		3,995
Total liabilities of discontinued operations	3,278		8,615
Net assets of discontinued operations	198		$ 7,252
Depreciation and amortization	215	379
Stock-based compensation	19	145
Gain on extinguishment of debt	(400)	$ 0
Expected cash proceeds	2,723
Less: net assets transferred	(8,840)
Less: expected disposal costs	(890)
Expected loss on sale of discontinued operations, before income taxes	(7,007)
Income tax expense	0
Expected loss on sale of discontinued operations	$ (7,007)
[1]The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Note 4 - In-license Agreement (

Note 4 - In-license Agreement (Details Textual) - Aguettant [Member] - PFS Products [Member] $ in Millions	Jul. 14, 2021 USD ($)
License Agreement, Term (Year)	10 years
License Agreement, Renewal Term (Year)	5 years
License Agreement, Milestone Payments to be Paid, Maximum	$ 24
License Agreement, Minimum Sales Obligation Term (Month)	12 months
Minimum [Member]
License Agreement, Percent of Revenue Share Payment to be Paid	40%
Maximum [Member]
License Agreement, Percent of Revenue Share Payment to be Paid	45%

Note 5 - Long-term Debt (Detail

Note 5 - Long-term Debt (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	May 30, 2019
Amortization of Debt Discount (Premium)	$ 38,000	$ 134,000
Loan Agreement with Oxford Finance LLC [Member]
Debt Instrument, Face Amount				$ 25,000,000
Long-Term Debt	3,300,000		$ 5,400,000
Interest Expense, Debt	100,000	400,000
Amortization of Debt Discount (Premium)	$ 39,000	$ 100,000

Note 6 - Leases (Details Textua

Note 6 - Leases (Details Textual) - USD ($)		3 Months Ended
	Mar. 26, 2021	Mar. 31, 2023	Jun. 30, 2023	Dec. 31, 2022	[1]	Dec. 12, 2012
Operating Lease, Right-of-Use Asset		$ 49,000		$ 96,000
Lessee, Operating Lease, Renewal Term (Year)						2 years
Lease for Corporate Headquarters in Hayward, California [Member]
Lessee, Operating Lease, Term of Contract (Year)	2 years 3 months
Lessee, Operating Lease, Monthly Rent	$ 17,000
Lessee, Operating Lease, Abated Rent Period (Month)	1 month
Operating Lease, Right-of-Use Asset	$ 400,000
Operating Lease, Expense		$ 50,000
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year			$ 50,000
[1]The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Details Textual)	Jul. 06, 2021	Jun. 08, 2021
Purported Shareholder v. Company - Violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 [Member]
Loss Contingency, Number of Defendants		2
Purported Shareholder v. Company - Alleged Misstatements as the Shareholder [Member]
Loss Contingency, Number of Defendants	10

Note 8 - Warrants (Details Text

Note 8 - Warrants (Details Textual) $ / shares in Units, $ in Thousands	Mar. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Dec. 29, 2022	Dec. 27, 2022 shares
Warrants and Rights Outstanding | $	$ 1,787	$ 7,098
Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	3.58
The 2022 Prefunded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares				2,632,898
Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares				4,227,052
Warrants and Rights Outstanding | $	$ 1,800
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 2.07
Warrants and Rights Outstanding, Measurement Input	0.658
Common Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	97.06
December 2022 Financing [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input			6
December 2022 Financing [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0

Note 8 - Warrants - Summary of

Note 8 - Warrants - Summary of Warrants Activity (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Outstanding, warrants (in shares) | shares	7,824,933
Pre-funded warrants exercised, warrants (in shares) | shares	2,632,898
Outstanding, warrants (in shares) | shares	5,192,035
Exercisable, warrants (in shares) | shares	964,983
Weighted Average [Member]
Outstanding, warrants, weighted average exercise price (in dollars per share) | $ / shares	$ 1.72
Pre-funded warrants exercised, warrants, weighted average exercise price (in dollars per share) | $ / shares	0.0001
Outstanding, warrants, weighted average exercise price (in dollars per share) | $ / shares	2.59
Exercisable, warrants, weighted average exercise price (in dollars per share) | $ / shares	$ 4.89

Note 9 - Stock-based Compensa_3

Note 9 - Stock-based Compensation (Details Textual) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares	$ 1.39
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value | $	$ 1.7
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years 2 months 12 days
The 2020 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	127,611
Amended ESPP [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	185,860
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)	12,906

Note 9 - Stock-based Compensa_4

Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock-based compensation expense	$ 569	$ 783
Research and Development Expense [Member]
Stock-based compensation expense	93	174
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	457	464
Discontinued Operatin [Member]
Stock-based compensation expense	$ 19	$ 145

Note 9 - Stock-based Compensa_5

Note 9 - Stock-based Compensation - Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Restricted stock units outstanding (in shares) | shares	82,778
Restricted stock units weighted average outstanding (in dollars per share) | $ / shares	$ 16.97
Granted (in shares) | shares	44,091
Weighted average grant date fair value, granted (in dollars per share) | $ / shares	$ 1.76
Vested (in shares) | shares	(34,606)
Weighted average grant date fair value, vested (in dollars per share) | $ / shares	$ 21.61
Forfeited (in shares) | shares	(643)
Weighted average grant date fair value, forfeited (in dollars per share) | $ / shares	$ 17.91
Restricted stock units outstanding (in shares) | shares	91,620
Restricted stock units weighted average outstanding (in dollars per share) | $ / shares	$ 7.89

Note 9 - Stock-based Compensa_6

Note 9 - Stock-based Compensation - Option Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Outstanding (in shares) | shares	725,623
Outstanding (in dollars per share) | $ / shares	$ 52.98
Granted (in shares) | shares	264,520
Granted, weighted-average exercise price (in dollars per share) | $ / shares	$ 1.76
Forfeited (in shares) | shares	(1,950)
Forfeited, weighted-average exercise price (in dollars per share) | $ / shares	$ 19.41
Expired (in shares) | shares	(90,802)
Expired, weighted-average exercise price (in dollars per share) | $ / shares	$ 83.75
Exercised (in shares) | shares	0
Exercised, weighted-average exercise price (in dollars per share) | $ / shares	$ 0
Outstanding (in shares) | shares	897,391
Outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 34.84
Outstanding, weighted-average remaining contractual life (Year)	6 years 10 months 24 days
Outstanding, aggregate intrinsic value | $	$ 0
Vested and exercisable options (in shares) | shares	459,397
Vested and exercisable options, weighted-average exercise price (in dollars per share) | $ / shares	$ 58.42
Vested and exercisable options, weighted-average remaining contractual life (Year)	4 years 8 months 12 days
Vested and exercisable options, aggregate intrinsic value | $	$ 0
Vested and expected to vest (in shares) | shares	897,391
Vested and expected to vest, weighted-average exercise price (in dollars per share) | $ / shares	$ 34.84
Vested and expected to vest, weighted-average remaining contractual life (Year)	6 years 10 months 24 days
Vested and expected to vest, aggregate intrinsic value | $	$ 0

Note 9 - Stock-based Compensa_7

Note 9 - Stock-based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details) - Performance Shares [Member] - Minimum [Member]	3 Months Ended
	Mar. 31, 2023
Expected term (in years) (Year)	6 years 3 months 18 days
Risk-free interest rate	3.90%
Expected volatility	94%
Expected dividend rate	0%

Note 10 - Net Income Per Share

Note 10 - Net Income Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
RSU's, ESPP, and Employee Stock Options [Member]
Antidilutive securities (in shares)	989,011	893,223
Warrant [Member]
Antidilutive securities (in shares)	5,192,035	883,833

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) $ / shares in Units, $ in Millions	Apr. 03, 2023 USD ($)	Apr. 25, 2023 $ / shares	Apr. 03, 2023 EUR (€)	Mar. 12, 2023 USD ($)
Subsequent Event [Member] | December 2022 Financing [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 1
Subsequent Event [Member] | Loan Agreement with Oxford Finance LLC [Member]
Repayments of Debt	$ 3.4
Subsequent Event [Member] | Aguettant [Member] | PFS Products [Member]
Licensing Agreement, Complementary Payment | €			€ 1,500,000
Subsequent Event [Member] | Aguettant [Member] | PFS Products [Member] | Maximum [Member]
Licensing Agreement, Milestone Payments	21
DSUVIA [Member] | Discontinued Operations [Member]
Disposal Group, Including Discontinued Operation, Maximum Amount in Sales-based Milestone				$ 116.5
Disposal Group, Including Discontinued Operation, Percentage of Royalty on Commercial Sales				15%
DSUVIA [Member] | Discontinued Operations [Member] | Department of Defense [Member]
Disposal Group, Including Discontinued Operation, Percentage of Royalty on Commercial Sales				75%
DSUVIA [Member] | Discontinued Operations [Member] | Subsequent Event [Member]
Disposal Group, Including Discontinued Operation, Maximum Amount in Sales-based Milestone	$ 116.5
Disposal Group, Including Discontinued Operation, Percentage of Royalty on Commercial Sales	15%		15%
Disposal Group, Including Discontinued operations, Percentage of Sales, Excluding Royalty Payments	20%		20%
DSUVIA [Member] | Discontinued Operations [Member] | Subsequent Event [Member] | Department of Defense [Member]
Disposal Group, Including Discontinued Operation, Percentage of Royalty on Commercial Sales	75%		75%